

has been lodged today with the Australian Securities and Investments Commission, meaning that the scheme has now become legally effective. Zenyth said its shareholders would receive payment of the share scheme consideration from CSL in the week commencing 13 November 2006. As a result of the court's approval of the scheme, Zenyth said it would become a wholly owned subsidiary of CSL and therefore its 2006 annual general meeting that was scheduled for 14 December 2006 would not be held.

BioPharmica Limited (BPH) today announced a new collaboration between Molecular Discovery Systems ("MDS"), a wholly owned subsidiary of BioPharmica and GE Healthcare. Biopharmica said the pilot study will use cell-based imaging equipment to analyse tissue from more than 500 breast cancer patients whose samples form part of the WA Research Tissue Network. Western Australian Premier Alan Carpenter announced the agreement today at an event held at the Western Australian Institute for Medical Research ("WAIMR"), home of the WA Research Tissue Network. BioPharmica said GE's IN Cell Analyzer imaging technology provides scientists with a way of seeing what is happening around genes, and in the process helps them to more quickly determine if the gene will be of use for new tests or treatments for diseases such as cancer and diabetes. BioPharmica director Charles Murphy said MDS will play a vital, synergistic role in BioPharmica's investment portfolio and enhance the capacity to invest into and commercialise world-leading Australian science.

Acrux Limited (ACR) today announced that on 30 October 2006 it received the payment of US\$1 million, due from its US licensee VIVUS following the submission to the US Food and Drug Administration ("FDA") of the new drug application for EvaMist. A further payment of US\$3 million will be due on approval of the application by the FDA, followed by royalties on sales, the company said. In the first quarter report, Acrux also filed its statement of cash flows for the period ending 30 September 2006. Cash reserves were \$16.6 million down from \$19.7 million in the previous quarter, representing a net cash outflow of \$3.1million for the period. Acrux said staff costs of \$1.4 million were higher than the previous quarter due to termination payments accrued at 30 June 2006, which also increased the amounts paid to directors in the quarter. Staff costs would be significantly lower in the remaining quarters of the year, the company said.



Sponsor Ad: Celebrate our 100millionth HP LaserJet printer entering the workforce. Register and WIN one of the world's most dependable printers for your business today.

[Disclaimer](#) [Contact SHAW](#) [Technical Help](#) [Privacy](#)

SHAW Stockbroking Sydney - 1800 636 625 Melbourne - 1800 150 009

EXCLUSIVE! Woolies Talks to egoli



Float Files: Is there meat in Patties' \$103m pie?



Reporting Season Calendar By Date

Reporting Season Calendar By Code



Grow your Profits Click Here



Adobe® Reader® DOWNLOAD HERE